Publications by authors named "Kuojun Ren"
Article Synopsis
- Anlotinib, a tyrosine kinase inhibitor, was studied for its effectiveness and safety when combined with a chemotherapy regimen (docetaxel, epirubicin, and cyclophosphamide) as neoadjuvant treatment for locally advanced triple-negative breast cancer (TNBC).
- The study involved 18 patients who received an average of nearly six treatment cycles; results showed a high overall response rate of 83.33% and a complete pathological response of 55.6%, indicating significant tumor reduction.
- The treatment had manageable side effects, with 27.8% of patients experiencing severe adverse events, but no participants had to stop treatment due to these effects, suggesting the combined regimen is worth further investigation
Introduction: The role of derived neutrophil-to-lymphocyte ratio (dNLR) in predicting the prognosis of patients with triple-negative breast cancer (TNBC) has not been well studied. Here, we attempted to investigate the significance of dNLR in predicting the prognosis of patients with surgical (nonmetastatic) TNBC.
Methods: A total of 281 patients diagnosed with surgical TNBC in The First Affiliated Hospital of University of Science and Technology of China from February 2005 to March 2015 were retrospectively included in this study.
[Effects of Ad-p53 plus fulvestrant on induced apoptosis in MCF-7 breast cancer cells].
Zhonghua Yi Xue Za Zhi
January 2015
Objective: To explore the apoptosis-inducing effect of Ad-p53 plus fulvestrant in MCF-7 breast cancer cells.
Methods: ER-positive MCF-7 breast cancer cells were used. MCF-7 cells were established with control, fulvestrant alone, Ad-p53 alone and Ad-p53 plus fulvestrant.